聚糖功能化纳米颗粒:基于纳米生物复合材料的胃的治疗策略
Yu Xu1, Yongxu Yuan2, Yanyan Cui2
1College of Food and Health, Zhejiang A&F University, Hangzhou, 311300, China.
ACS applied materials & interfaces
|March 11, 2026
概括
改性纳米颗粒 (Se NPs) 通过提高生物可用性和减少炎症,有效治疗胃. 这些BSP-SeNP对胃肠道健康有显著的前景.
科学领域:
- 纳米医学是一种纳米医学.
- 胃肠病学 胃肠病学
- 生物材料是一种生物材料.
背景情况:
- 胃 (GU) 存在治疗挑战,包括高复发率和副作用.
- 纳米颗粒 (SeNP) 为GU治疗提供抗氧化和抗炎功效.
- 不良的稳定性和生物利用性限制了当前的Se NP应用.
研究的目的:
- 为了合成和评估BSP修改的Se NPs (BSP-Se NPs) 以加强胃治疗.
- 在体内调查BSP-SeNP的稳定性,生物可用性和治疗疗效.
主要方法:
- 用布莱蒂拉条纹多糖 (BSP) 稳定Se NPs的合成.
- BSP-Se NPs的粒子大小和分散的表征.
- 在乙醇诱导的胃潰瘍小鼠模型中的BSP-SeNP体内评估.
主要成果:
- BSP-Se NPs显示出良好的分散 (77.24 ± 3.17 nm) 和改善的生物可用性.
- BSP-Se NPs显示在胃组织中具有优先积累和延长的循环.
- 观察到指数显著降低,抑制炎症因素,改善组织损伤.
结论:
- 通过提高生物可用性和具有抗炎和抗氧化特性,BSP-SeNP有效治疗乙醇诱导的胃.
- BSP-Se NPs显示出作为胃的稳定和生物可用治疗剂的潜力.
- 这项研究强调了BSP-SeNP在流行胃肠道疾病中的治疗潜力.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.8K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.4K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K
Peptic Ulcer Disease IV: Management
602
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
602
Peptic Ulcer Disease I: Introduction
982
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
982


